Patents by Inventor Andrew Sewell
Andrew Sewell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11850264Abstract: The present disclosure relates to a new T-cell receptor (TCR), in particular at least one complementarity-determining region (CDR) thereof; a T-cell expressing said TCR; a clone expressing said TCR; a vector encoding said TCR; a soluble version of said TCR; a pharmaceutical composition or immunogenic agent or bispecific or vaccine comprising said TCR, said cell, said clone or said vector; said TCR or said cell or said clone or said vector or said pharmaceutical composition or immunogenic agent or bispecific or vaccine for use in the treatment of cancer; a method of treating cancer using said TCR, said cell, said clone, said vector, said pharmaceutical composition, immunogenic agent, bispecific or vaccine comprising said TCR; and a ligand with which said TCR binds.Type: GrantFiled: May 19, 2020Date of Patent: December 26, 2023Assignee: University College Cardiff Consultants Ltd.Inventors: Andrew Sewell, Garry Dolton
-
Patent number: 11725039Abstract: The present disclosure relates to a new T-cell receptor (TCR), in particular at least one complementarity-determining region (CDR) thereof; a T-cell expressing said TCR; a clone expressing said TCR; a vector encoding said TCR; a soluble version of said TCR; a pharmaceutical composition or bispecific comprising said TCR, said cell, said clone or said vector; use of said TCR or said cell or said clone or said vector or said pharmaceutical composition or bispecific to treat cancer; and a method of treating cancer using said TCR, said cell, said clone, said vector, said pharmaceutical composition or bispecific comprising said TCR.Type: GrantFiled: April 24, 2020Date of Patent: August 15, 2023Assignee: University College Cardiff Consultants Ltd.Inventors: Andrew Sewell, Garry Dolton
-
Publication number: 20220233662Abstract: The present disclosure relates to a new peptide; a new fusion polypeptide, a polynucleotide or vector encoding same; a pharmaceutical composition or immunogenic composition or vaccine comprising said peptide; use of said peptide, vector, pharmaceutical composition, immunogenic composition or vaccine to treat cancer; a method of treating cancer using said peptide, fusion polypeptide, polynucleotide, vector, pharmaceutical composition, immunogenic composition or vaccine; an ex vivo method of stimulating and/or amplifying T-cells; and a combination therapeutic for the treatment of cancer comprising said peptide fusion polypeptide, polynucleotide, vector, pharmaceutical composition, immunogenic composition or vaccine.Type: ApplicationFiled: December 30, 2021Publication date: July 28, 2022Inventors: Andrew SEWELL, Garry DOLTON
-
Publication number: 20210403528Abstract: The present disclosure relates to a new T-cell receptor (TCR), in particular at least one complementarity-determining region (CDR) thereof; a T-cell expressing said TCR; a clone expressing said TCR; a vector encoding said TCR; a soluble version of said TCR; a pharmaceutical composition or bispecific comprising said TCR, said cell, said clone or said vector; use of said TCR or said cell or said clone or said vector or said pharmaceutical composition or bispecific to treat cancer; and a method of treating cancer using said TCR, said cell, said clone, said vector, said pharmaceutical composition or bispecific comprising said TCR.Type: ApplicationFiled: May 21, 2021Publication date: December 30, 2021Inventors: Andrew SEWELL, Garry DOLTON
-
Patent number: 11078252Abstract: The present disclosure relates to a new T-cell receptor (TCR), in particular at least one complementarity-determining region (CDR) thereof; a T-cell expressing said TCR; a clone expressing said TCR; a vector encoding said TCR; a soluble version of said TCR; a pharmaceutical composition or bispecific comprising said TCR, said cell, said clone or said vector; use of said TCR or said cell or said clone or said vector or said pharmaceutical composition or bispecific to treat cancer; and a method of treating cancer using said TCR, said cell, said clone, said vector, said pharmaceutical composition or bispecific comprising said TCR.Type: GrantFiled: January 20, 2021Date of Patent: August 3, 2021Assignee: University College Cardiff Consultants Ltd.Inventors: Andrew Sewell, Garry Dolton
-
Publication number: 20210196807Abstract: The present disclosure relates to a new anti-cancer peptide; a vector encoding same; a pharmaceutical composition or immunogenic agent or bispecific or vaccine comprising said anti-cancer peptide; use of said anti-cancer peptide, vector, pharmaceutical composition, immunogenic agent, bispecific or vaccine to treat cancer; a method of treating cancer using said anti-cancer peptide, vector, pharmaceutical composition, immunogenic agent, bispecific or vaccine; and a combination therapeutic for the treatment of cancer comprising said anti-cancer peptide, vector, pharmaceutical composition, immunogenic agent, bispecific or vaccine.Type: ApplicationFiled: December 11, 2020Publication date: July 1, 2021Inventors: Andrew SEWELL, Garry DOLTON
-
Publication number: 20210147506Abstract: The present disclosure relates to a new T-cell receptor (TCR), in particular at least one complementarity-determining region (CDR) thereof; a T-cell expressing said TCR; a clone expressing said TCR; a vector encoding said TCR; a soluble version of said TCR; a pharmaceutical composition or bispecific comprising said TCR, said cell, said clone or said vector; use of said TCR or said cell or said clone or said vector or said pharmaceutical composition or bispecific to treat cancer; and a method of treating cancer using said TCR, said cell, said clone, said vector, said pharmaceutical composition or bispecific comprising said TCR.Type: ApplicationFiled: January 20, 2021Publication date: May 20, 2021Inventors: Andrew SEWELL, Garry DOLTON
-
Publication number: 20200369742Abstract: The present disclosure relates to a new T-cell receptor (TCR), in particular at least one complementarity-determining region (CDR) thereof; a T-cell expressing said TCR; a clone expressing said TCR; a vector encoding said TCR; a soluble version of said TCR; a pharmaceutical composition or bispecific comprising said TCR, said cell, said clone or said vector; use of said TCR or said cell or said clone or said vector or said pharmaceutical composition or bispecific to treat cancer; and a method of treating cancer using said TCR, said cell, said clone, said vector, said pharmaceutical composition or bispecific comprising said TCR.Type: ApplicationFiled: April 24, 2020Publication date: November 26, 2020Inventors: Andrew SEWELL, Garry DOLTON
-
Publication number: 20200316124Abstract: The present disclosure relates to a new T-cell receptor (TCR), in particular at least one complementarity-determining region (CDR) thereof; a T-cell expressing said TCR; a clone expressing said TCR; a vector encoding said TCR; a soluble version of said TCR; a pharmaceutical composition or immunogenic agent or bispecific or vaccine comprising said TCR, said cell, said clone or said vector; said TCR or said cell or said clone or said vector or said pharmaceutical composition or immunogenic agent or bispecific or vaccine for use in the treatment of cancer; a method of treating cancer using said TCR, said cell, said clone, said vector, said pharmaceutical composition, immunogenic agent, bispecific or vaccine comprising said TCR; and a ligand with which said TCR binds.Type: ApplicationFiled: May 19, 2020Publication date: October 8, 2020Inventors: Andrew SEWELL, Garry DOLTON
-
Publication number: 20200123198Abstract: Disclosed are methods for identifying immunogenic peptides, and tools and/or reagents to be used in those methods. More specifically, the invention relates to combinatorial peptide library screening for synthetic antigenic peptides recognized by natural T-cell receptors.Type: ApplicationFiled: October 3, 2017Publication date: April 23, 2020Applicant: The Council of the Queensland Institute of Medical Research (QIMR)Inventors: Andrew Sewell, John Miles
-
Publication number: 20150118327Abstract: Compounds, e.g., of formula (I) and (Ia), pharmaceutical compositions comprising the compounds and methods of using the compounds and pharmaceutical compositions for treating pain disorders, e.g., disorders associated with cephalic pain, are provided.Type: ApplicationFiled: October 9, 2014Publication date: April 30, 2015Inventor: Richard Andrew Sewell
-
Patent number: 8859579Abstract: Compounds, e.g., of formula (I) and (Ia), pharmaceutical compositions comprising the compounds and methods of using the compounds and pharmaceutical compositions for treating pain disorders, e.g., disorders associated with cephalic pain, are provided.Type: GrantFiled: March 20, 2009Date of Patent: October 14, 2014Inventor: Richard Andrew Sewell
-
Publication number: 20090264456Abstract: Compounds, e.g., of formula (I) and (Ia), pharmaceutical compositions comprising the compounds and methods of using the compounds and pharmaceutical compositions for treating pain disorders, e.g., disorders associated with cephalic pain, are provided.Type: ApplicationFiled: March 20, 2009Publication date: October 22, 2009Inventor: Richard Andrew Sewell
-
Publication number: 20070191278Abstract: This invention is directed to a method for inhibiting cytotoxic T lymphocyte (CTL) activity in which soluble CD8 is used as the inhibitor. The invention is further directed to soluble forms of the CD8 molecule which can be administered to a patient. The method of this invention is particularly useful for immunosuppressive therapy in which inhibition of CTL activity is desirable, for example, in patients undergoing transplantation.Type: ApplicationFiled: April 4, 2007Publication date: August 16, 2007Applicant: Avidex LimitedInventors: Bent Jakobsen, George Gao, Ulrich Gerth, Andrew Sewell
-
Publication number: 20070105822Abstract: Statins are able to block the mevalonate pathway at an early stage, preventing build up of isopentenyl pyrophosphate by nitrogen containing bisphosphonates by blocking the pathway further downstream, with medicaments containing statins being administered at an appropriate time being able to thereby prevent the build up of IPP, which has been found to activate ?? T cells and cause the acute phase response associated with the nitrogen containing bisphosphonates.Type: ApplicationFiled: November 29, 2004Publication date: May 10, 2007Inventor: Andrew Sewell
-
Publication number: 20070031442Abstract: An antigen presenting molecule is capable of increasing sensitivity of a cytotoxic T lymphocyte to an antigen by interaction with a T cell receptor and CD8 coreceptor thereon, when the antigen presentation molecule displays an increased avidity for the CD8, compared to the molecule encoded by SEQ ID NO. 1 in vivo. Levels of avidity of the molecule for CD8 in excess of the pMHC I/TCR interaction result in the molecule being a pan activator for MHC Class I specific cytotoxic T cells.Type: ApplicationFiled: February 17, 2004Publication date: February 8, 2007Inventor: Andrew Sewell
-
Patent number: 6164845Abstract: Processing of photographic material is carried out by sensing the quantity of material passing through a processor and supplying replenishment solution in accordance therewith. The level of solution in the processing tanks is also sensed during processing, and a second solution is supplied in the event that the level falls below a predetermined value. The second solution is less concentrated than the normal replenishment solution, thereby to maintain the chemical activity of the tank closer to its required, seasoned state. Furthermore, by controlling the solution levels during processing, less replenishment solution need be added during normal replenishment, thus minimizing the amount of solutions needed.Type: GrantFiled: October 6, 1998Date of Patent: December 26, 2000Assignee: Eastman Kodak CompanyInventors: Anthony Earle, Andrew Sewell, Sheridan Vincent